BMC Pharmacology and Toxicology · 2016 · 19 citations · 20 references
Life SciencesPharmacologyAntimicrobial PharmacologyAntimicrobial PharmacotherapyAntimicrobial ResistanceAntibacterial PharmacologyAntibacterial ResistanceAntibiotic ResistanceMultidrug ResistanceAntimicrobial Drug DevelopmentBroth MicrodilutionKlebsiella Pneumoniae ResistanceMulti-drug ResistanceMultidrug-resistant Gram-negative BacteriaResistance Mechanisms In Gram-negative Bacteria
BACKGROUND: Bacterial multidrug resistance (MDR) constitutes a major hurdle in the treatment of infectious diseases worldwide. The present study was designed to evaluate the antibacterial activities of synthetic p-toluenesulfonyl-hydrazinothiazoles against multidrug resistant Gram-negative bacteria. METHODS: The broth microdilution method was used to determine the minimal inhibitory concentrations (MIC). RESULTS: The results demonstrated that the best activities were obtained with hydrazinoselenazoles. p-Chloro-benzyliden-selenosemicarbazide, 4-methyl-2-[(4-chloro-benzyliden)-hydrazinyl]-1,3-selenazole, p-chloro-benzoyl-selenosemicarbazide and 4-chloromethyl-2-[(4-chlorobenziliden)-N-acetyl-hydrazinyl]-1,3-selenazole were more active than the choramphenicol on Klebsiella pneumoniae KP63. Tested alone, the lowest MIC value of 16 mg/L was obtained with p-methoxy-benzyliden-selenosemicarbazide against Enterobacter aerogenes ATCC13048, K. pneumoniae ATCC112296 and KP55. Tested in the presence of an efflux pump inhibitor, phenylalanine arginine β-naphthylamide (PAβN), the activity of p-chloro-benzyliden-selenosemicarbazide, 4-methyl-2-[(4-chloro-benzyliden)-hydrazinyl]-1,3-selenazole, p-chloro-benzoyl-selenosemicarbazide and p-methoxy-benzyliden-selenosemicarbazide significantly increased with MIC values below 10 mg/L obtained respectively on 43.8 %, 31.3 %, 62.5 % and 100 % of the 16 tested bacterial strains. The lowest MIC value of 0.5 mg/L in the presence of PAβN was recorded with p-chloro-benzoyl-selenosemicarbazide against Escherichia coli ATCC8739 and KP55 as well as p-methoxy-benzyliden-selenosemicarbazide against E. aerogenes KP55. p-Chloro-benzyliden-selenosemicarbazide and p-chloro-benzoyl-selenosemicarbazide contained the same pharmacophore as p-methoxy-benzyliden-selenosemicarbazide. CONCLUSION: This study indicates that p-chloro-benzyliden-selenosemicarbazide, p-chloro-benzoyl-selenosemicarbazide and p-methoxy-benzyliden-selenosemicarbazide could be explored more to develop novel antimicrobial drugs to fight MDR bacterial infections.
20
S.P.N. Mativandlela, Namrita Lall, J.J.M. Meyer · South African Journal of Botany · 2006 · 183 citations · Full text
Aimé G. Fankam, Victor Kuete, Igor K. Voukeng et al. · BMC Complementary and Alternative Medicine · 2011 · 180 citations · Full text